This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The American College Of Obstetricians And Gynecologists Committee On Genetics And The Society For Maternal-Fetal Medicine Publications Committee Recommend Noninvasive Prenatal Testing For Fetal Aneuploidy

SAN DIEGO, Nov. 21, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced that the American College of Obstetricians and Gynecologists (ACOG) Committee on Genetics and the Society for Maternal-Fetal Medicine (SMFM) Publications Committee issued a joint Committee Opinion on November 20, 2012, recommending that cell-free fetal DNA testing be offered to patients at increased risk of aneuploidy.  It can also be used as a follow-up test for women with a positive first-trimester or second-trimester screening test result.

Previously, the ACOG recommended that women, regardless of maternal age, be offered prenatal assessment for aneuploidy by screening or invasive prenatal diagnosis. The ACOG Committee on Genetics and the SMFM Publications Committee now recommend that women at increased risk of aneuploidy be offered cell-free fetal DNA as an option that can be used as a primary screening test based on the following indications:

  • Maternal age 35 years or older at delivery.
  • Fetal sonographic findings indicating an increased risk of aneuploidy.
  • History of a prior pregnancy with a trisomy.
  • Positive test result for aneuploidy, including first trimester, sequential, or integrated screen, or a quadruple screen.
  • Parental balanced robertsonian translocation with increased risk for fetal trisomy 13 or 21.

The Committee Opinion also recommended that "cell-free fetal DNA testing should not be offered to low-risk women or women with multiple gestations because it has not been sufficiently evaluated in these groups." Further, the Committee Opinion stated that "pre-test counseling should be an informed patient choice after pre-test counseling and should not be part of routine prenatal laboratory assessment.  A patient with a positive test result should be referred for genetic counseling and offered invasive prenatal diagnosis for confirmation of test results."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,101.20 +77.14 0.43%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs